🔗 Share this article

Given that the United States continues making sweeping revisions to its vaccination recommendations, one figure has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by questioning COVID-19 shots in the global health crisis and has concentrated on potential fatalities following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Public health authorities planned to announce sweeping changes to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of step with much of the international standard with insufficient data for improved outcomes. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to lead the division this year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain childhood immunization guidelines in the US in order to be more like Denmark, a nation with comprehensive healthcare and a population about the size of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Høeg has little discernible background in pharmaceutical research, regulation or management, which has been customary for past directors of the CBER. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former heads of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran CBER have had.”

This division has an enormous workload at the agency, the former commissioner emphasized.

“The public just zeroes in on the new drug program, but the generic drug division clears a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one need to be supervised,” Dr. Woodcock said. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant management aspect to the job, which manages more than 5,000 employees. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this appointment represents more teamwork among FDA leaders on immunizations, a representative responded that the “inquiries rely on flawed presumptions”.

“Her resume aligns with the duties of her position,” the official said, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial one-day medication authorization process that reportedly troubled her preceding directors. “How are these drugs being chosen for this voucher program? Who is making the decisions?” Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards laxer regulations of all drugs, except for shots.”

Documented Past Work on Immunizations

Concerning immunizations, Høeg has a more documented, if concerning, history, Howard observe. She released a analysis using non-validated volunteer-provided data to determine the rate of heart inflammation after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are riskier than they are.

Among her “wish list” for the new government encompassed revising regulations for recently developed shots and halting “unnecessary” vaccines, she said following the vote on a audio program. At the agency, Høeg has according to sources proposed barring teenage boys from receiving Covid vaccines.

“She is an thorough dogmatist who commences with her preconceived notions and works backwards to retrofit the data in a extremely disingenuous, dishonest manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|